These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37944991)

  • 21. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
    Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Kayser S; Krzykalla J; Elliott MA; Norsworthy K; Gonzales P; Hills RK; Baer MR; Ráčil Z; Mayer J; Novak J; Žák P; Szotkowski T; Grimwade D; Russell NH; Walter RB; Estey EH; Westermann J; Görner M; Benner A; Krämer A; Smith BD; Burnett AK; Thiede C; Röllig C; Ho AD; Ehninger G; Schlenk RF; Tallman MS; Levis MJ; Platzbecker U
    Leukemia; 2017 Nov; 31(11):2347-2354. PubMed ID: 28322237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.
    Gill H; Raghupathy R; Lee CYY; Yung Y; Chu HT; Ni MY; Xiao X; Flores FP; Yim R; Lee P; Chin L; Li VWK; Au L; Au WY; Ma ESK; Mohan D; Kumana CR; Kwong YL
    BMC Cancer; 2023 Feb; 23(1):141. PubMed ID: 36765318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lengfelder E; Hofmann WK; Nowak D
    Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
    Mandegary A; Hosseini R; Ghaffari SH; Alimoghaddam K; Rostami S; Ghavamzadeh A; Ghahremani MH
    Ann Oncol; 2010 Sep; 21(9):1884-1890. PubMed ID: 20164150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide: mechanisms of action.
    Davison K; Mann KK; Miller WH
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
    Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
    Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
    Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Fouzia NA; Sharma V; Ganesan S; Palani HK; Balasundaram N; David S; Kulkarni UP; Korula A; Devasia AJ; Nair SC; Janet NB; Abraham A; Mani T; Lakshmanan J; Balasubramanian P; George B; Mathews V
    Br J Haematol; 2021 Jan; 192(2):292-299. PubMed ID: 33216980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    Firkin F; Roncolato F; Ho WK
    Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
    Chen X; Fan S; Zhao Y; Zhou J
    Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.
    Yanada M; Tsuzuki M; Fujita H; Fujimaki K; Fujisawa S; Sunami K; Taniwaki M; Ohwada A; Tsuboi K; Maeda A; Takeshita A; Ohtake S; Miyazaki Y; Atsuta Y; Kobayashi Y; Naoe T; Emi N;
    Blood; 2013 Apr; 121(16):3095-102. PubMed ID: 23412094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
    Aznab M; Rezaei M
    Hematol Oncol; 2017 Mar; 35(1):113-117. PubMed ID: 26310595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
    Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
    Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
    Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
    Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R
    Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
    Zaki Dizaji M; Ghaffari SH; Hosseini E; Alizadeh N; Rostami S; Momeny M; Alimoghaddam K; Ghavamzadeh A
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e21-e30. PubMed ID: 27770503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.